# Cab ula PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cab-ula

> The next catalyst for cab ula, sponsored by GSK plc (GSK), is its topline data readout, Aug to Nov 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | cab ula |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [HIV](https://sec-api.dev/indications/hiv) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug to Nov 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: HIV.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07650916 (A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-13 (ESTIMATED); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT07650916

### August 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: HIV.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07650916 (A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-13 (ESTIMATED); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT07650916

## Same indication

- [Alimatravir](https://sec-api.dev/pdufa/alimatravir) (MRK)
- [Tivicay (dolutegravir sodium)](https://sec-api.dev/pdufa/dolutegravir) (GSK)
- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cab-ula.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cab ula PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cab-ula

```bibtex
@misc{secapidev_pdufa_cab_ula_20261116,
  title        = {Cab ula PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cab-ula}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cab_ula_20261116","title":"Cab ula PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cab-ula","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
